Zobrazeno 1 - 10
of 312
pro vyhledávání: '"YUSUKE OKUMA"'
Autor:
Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2909-2923 (2023)
Abstract Background Risk factors for predicting pneumonitis during durvalumab consolidation after chemoradiotherapy (CRT) in locally advanced non‐small cell lung cancer (LA‐NSCLC) are still lacking. Extracellular vesicles (EVs) play a crucial rol
Externí odkaz:
https://doaj.org/article/c26bd9ec8eaf4da5b06f23bbc99b43dc
Autor:
Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100636- (2024)
Introduction: Osimertinib (OSI), a third-generation EGFR tyrosine kinase inhibitor, is the standard treatment for patients with naive EGFR-mutant NSCLC. Nevertheless, information on how the mutation subtype affects disease progression after the failu
Externí odkaz:
https://doaj.org/article/2ca2a2673ed6490287b76ea50654af86
Autor:
Masahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, Yukiko Shimoda, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12388-12401 (2023)
Abstract Background It is still unclear whether patients with advanced non‐small cell lung cancer (NSCLC), with disease progression after initial immune checkpoint inhibitor (ICI) therapy, would benefit from ICIs readministration. Patients and Meth
Externí odkaz:
https://doaj.org/article/7ac7d1fe4d974671b57fe0cc9e30f8bb
Autor:
Saori Takata, Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Masashi Ishihara, Kazuya Horiuchi, Yasuhiro Kato, Shinnosuke Ikemura, Hideyuki Nakagawa, Yoshiro Nakahara, Yoshitaka Seki, Akihiro Bessho, Nobumasa Takahashi, Kentaro Hayashi, Takeo Endo, Kiyoshi Takeyama, Toshiya Maekura, Nagio Takigawa, Akikazu Kawase, Makoto Endoh, Kenji Nemoto, Kazuma Kishi, Kenzo Soejima, Yusuke Okuma, Kenichi Yoshimura, Daisuke Saigusa, Yae Kanai, Koji Ueda, Akira Togashi, Noriyuki Matsutani, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The exosome-focused translational research for afatinib (EXTRA) study is the first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in patients with epidermal growth factor receptor ( EGFR ) mutation
Externí odkaz:
https://doaj.org/article/f62d5588d7244b819241b0e2adeb0dc1
Autor:
Hitomi Jo, MD, PhD, Tatsuya Yoshida, MD, PhD, Shigehiro Yagishita, MD, PhD, Mayu Ohuchi, PhD, Yuji Matsumoto, MD, PhD, Yuki Shinno, MD, PhD, Yusuke Okuma, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhisa Takahashi, MD, PhD, Noriko Motoi, MD, PhD, Akinobu Hamada, PhD, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100474- (2023)
Introduction: Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced NSCLC. Nevertheless, these responses are limited to a few patients, and most responders have disease progression. The purpose of this stud
Externí odkaz:
https://doaj.org/article/fbc7fcbfc26745ea85440370d0442d63
Autor:
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients wi
Externí odkaz:
https://doaj.org/article/3e86b2e7f167471e865402ee946d66a0
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1668-1672 (2021)
Abstract Background Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation a
Externí odkaz:
https://doaj.org/article/91860ec955834aad8eff9c58cb249c2c
Autor:
Minami Koriyama, Yoshitaka Okamoto, Takeshi Suzuki, Tomohisa Iinuma, Heizaburou Yamamoto, Yusuke Okuma, Sawako Hamasaki, Daiju Sakurai, Toyoyuki Hanazawa, Syuji Yonekura
Publikováno v:
Allergology International, Vol 71, Iss 1, Pp 144-146 (2022)
Externí odkaz:
https://doaj.org/article/2cd24617a4804eb98ebe8ee237553b18
Autor:
Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100311- (2022)
Introduction: Lorlatinib (LOR) or pemetrexed-based chemotherapy (PEM) is the standard treatment after failure of a second-generation ALK tyrosine kinase inhibitor, such as alectinib, in patients with ALK-positive NSCLC. Nevertheless, there have been
Externí odkaz:
https://doaj.org/article/e34bc5fff85145d196a7f16895ceb314
Autor:
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7418-7427 (2020)
Abstract Thymic carcinoma (TC) is a rare cancer with minimal evidence of survival following palliative‐intent chemotherapy. Sunitinib, everolimus, and pembrolizumab have been proposed as active agents based on previous phase II trials. In this phas
Externí odkaz:
https://doaj.org/article/76f9d6f96b7745e6b7c709b7da86e565